Lilly Expands LillyDirect Platform to Support Alzheimer's Disease Care

Eli Lilly and Company announced, that it has expanded its LillyDirect platform to improve access to Alzheimer’s disease care in the U.S. The enhancement includes tools that connect patients to independent in-person and telehealth providers, addressing long wait times and access issues—particularly in rural and underserved communities.

The new features do not include direct pharmacy services but instead focus on improving education and facilitating diagnosis and care coordination. Resources include Healthgrades, a doctor locator tool, and Synapticure, a specialized telehealth provider offering care navigation, neurology consultations within two weeks, and 24/7 support.

Lilly emphasized the importance of early diagnosis, noting that up to 3,000 Americans with Alzheimer's progress daily from mild to more severe stages, where treatment options are more limited. The company aims to empower patients to access timely and accurate care and plans to expand LillyDirect internationally.